Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties
- 17 July 2014
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (15), 3604-3619
- https://doi.org/10.1111/bph.12720
Abstract
Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors. Accumulating evidence in a broad range of experimental procedures supports the notion that the psychotropic effects of agomelatine are due to the synergy between its melatonergic and 5-hydroxytryptaminergic effects. The recent demonstration of the existence of heteromeric complexes of MT1 and MT2 with 5-HT2C receptors at the cellular level may explain how these two properties of agomelatine translate into a synergistic action that, for example, leads to increases in hippocampal proliferation, maturation and survival through modulation of multiple cellular pathways (increase in trophic factors, synaptic remodelling, glutamate signalling) and key targets (early genes, kinases). The present review focuses on the pharmacological properties of this novel antidepressant. Its mechanism of action, strikingly different from that of conventional classes of antidepressants, opens perspectives towards a better understanding of the physiopathological bases underlying depression.This publication has 137 references indexed in Scilit:
- Novel melatonin-based therapies: potential advances in the treatment of major depressionThe Lancet, 2011
- NMDA receptor blockade at rest triggers rapid behavioural antidepressant responsesNature, 2011
- Knockdown of Clock in the Ventral Tegmental Area Through RNA Interference Results in a Mixed State of Mania and Depression-Like BehaviorBiological Psychiatry, 2010
- Ketamine and the next generation of antidepressants with a rapid onset of actionPharmacology & Therapeutics, 2009
- Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesisMolecular Psychiatry, 2009
- Neurogenesis-Dependent and -Independent Effects of Fluoxetine in an Animal Model of Anxiety/DepressionNeuron, 2009
- Circadian rhythm disturbances in depressionHuman Psychopharmacology: Clinical and Experimental, 2008
- Chronic disruption of circadian rhythms impairs hippocampal memory in the ratBrain Research Bulletin, 2008
- Regionally Specific Regulation of ERK MAP Kinase in a Model of Antidepressant-Sensitive Chronic DepressionBiological Psychiatry, 2008
- Circadian genes, rhythms and the biology of mood disordersPharmacology & Therapeutics, 2007